Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer
This trial is active, not recruiting.
|Treatments||radiofrequency ablation, cytokine-induced killer cells|
|Sponsor||The First People's Hospital of Changzhou|
|Start date||July 2015|
|End date||June 2038|
|Trial size||10 participants|
|Trial identifier||NCT02490748, cervical001|
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.
|Intervention model||parallel assignment|
time frame: 1 year
Female participants from 30 years up to 70 years old.
Inclusion Criteria: - They were systematic reviews based on randomized controlled trials (rcts). They were phase II rcts comparing chemotherapy with other systemic therapy agents or with no further treatment for recurrent, metastatic, or persistent cervical cancer. they reported at least one of these outcomes: complete or partial response rate, overall or progression-free survival rate, adverse effects, or healthrelated quality of life (rcts reporting on heterogeneous populations—for example, women at a range of disease stages—were included if results were given separately for patients with recurrent, metastatic, or persistent cervical cancer). Exclusion Criteria: - studies evaluating the role of radiotherapy administered with chemotherapy, or second- or subsequent-line therapy options.
|Official title||Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer|
|Description||The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cervical cancer.|
Call for more information